Intensive lipid lowering and non-statin therapy in PAD (targets and limb outcomes)
Type
ModificationConfidence
92%
Created
Apr 19, 2026
Evidence
1 source
Rationale
The 2026 ACC/AHA Lower Extremity PAD guideline (PMID 41252847) directly supersedes the previously cited [@acc2025-f] for the recommendation on adding ezetimibe or a PCSK9 inhibitor in very high-risk PAD patients who do not achieve LDL-C targets on statins alone. Per the stale guideline replacement instructions, [@acc2025-f] is replaced with [@acc2026] for this claim. No other content changes are warranted as the surrounding evidence (HPS, 4S, FOURIER, ODYSSEY OUTCOMES) remains accurate and current.
Evidence
Content Changes
All patients with peripheral arterial disease (PAD) should receive high-intensity statin therapy unless contraindicated. The Heart Protection Study (HPS) and Scandinavian Simvastatin Survival Study (4S) trials demonstrated significant cardiovascular risk reduction with statin therapy (Heart Protection 2002),[@4s1994?]. For very high-risk patients, particularly those with concomitant diabetes mellitus, who do not achieve target low-density lipoprotein cholesterol (LDL-C) levels with statins alone, the addition of ezetimibe or a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor is recommended (ACC 2026). The FOURIER and ODYSSEY OUTCOMES trials support this escalation strategy, with PAD subgroup analyses demonstrating both cardiovascular and limb benefits from PCSK9 inhibition (Sabatine 2017)📄,(Schwartz 2018)📄.
All patients with peripheral arterial disease (PAD) should receive high-intensity statin therapy unless contraindicated. The Heart Protection Study (HPS) and Scandinavian Simvastatin Survival Study (4S) trials demonstrated significant cardiovascular risk reduction with statin therapy (Heart Protection 2002),[@4s1994?]. For very high-risk patients, particularly those with concomitant diabetes mellitus, who do not achieve target low-density lipoprotein cholesterol (LDL-C) levels with statins alone, the addition of ezetimibe or a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor is recommended (Das 2025). The FOURIER and ODYSSEY OUTCOMES trials support this escalation strategy, with PAD subgroup analyses demonstrating both cardiovascular and limb benefits from PCSK9 inhibition (Sabatine 2017)📄,(Schwartz 2018)📄.
All patients with peripheral arterial disease (PAD) should receive high-intensity statin therapy unless contraindicated. The Heart Protection Study (HPS) and Scandinavian Simvastatin Survival Study (4S) trials demonstrated significant cardiovascular risk reduction with statin therapy (Heart Protection 2002),[@4s1994?]. For very high-risk patients, particularly those with concomitant diabetes mellitus, who do not achieve target low-density lipoprotein cholesterol (LDL-C) levels with statins alone, the addition of ezetimibe or a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor is recommended (ACC 2026). The FOURIER and ODYSSEY OUTCOMES trials support this escalation strategy, with PAD subgroup analyses demonstrating both cardiovascular and limb benefits from PCSK9 inhibition (Sabatine 2017)📄,(Schwartz 2018)📄.